Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi-Aventis’ CEO Pipeline: R&D Chief Le Fur Tapped To Succeed Dehecq

Executive Summary

Incoming Sanofi-Aventis CEO Gerard Le Fur will bring considerable research and development experience to the helm of the French drug maker

You may also be interested in...



Sanofi CEO succession finalized

Sanofi-Aventis' Board of Directors formally appoints Gerard Le Fur to succeed Jean-Francois DeHecq as the firm's CEO, effective Jan. 1, during a Dec. 14 meeting; DeHecq will remain board chairman. Le Fur, who currently serves as senior exec VP-science and medical affairs, was nominated for the post in May (1"The Pink Sheet" June 5, 2006, p. 11)...

Sanofi CEO succession finalized

Sanofi-Aventis' Board of Directors formally appoints Gerard Le Fur to succeed Jean-Francois DeHecq as the firm's CEO, effective Jan. 1, during a Dec. 14 meeting; DeHecq will remain board chairman. Le Fur, who currently serves as senior exec VP-science and medical affairs, was nominated for the post in May (1"The Pink Sheet" June 5, 2006, p. 11)...

Bristol Feels Plavix And Pravachol Pain; Does Relief Lie In Conservative R&D?

As Bristol-Myers Squibb prepares to weather patent losses for its two top-selling products - Pravachol and Plavix - the firm is sticking by a conservative approach to research & development

Related Content

UsernamePublicRestriction

Register

PS047251

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel